Patents by Inventor John W. M. Mackinnon

John W. M. Mackinnon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5103020
    Abstract: A method for the preparation of 3-(2-aminoethyl)-N-methyl-1H-indole-5-methanesulphonamide by reaction of 4-hydrazino-N-methylbenzenemethanesulphonamide and 4-chloro-1-hydroxybutanesulphonic acid, sodium salt in the presence of an acid.
    Type: Grant
    Filed: June 20, 1991
    Date of Patent: April 7, 1992
    Assignee: Glaxo Group Limited
    Inventors: Frederick D. Albinson, John W. M. MacKinnon, Derek L. Crookes
  • Patent number: 4777179
    Abstract: The invention provides compounds of the general formula ##STR1## and physiologically acceptable salts and hydrates thereof, in which one of R.sub.1 and R.sub.2 represents hydrogen, halogen or a C.sub.1-4 alkyl group which may be optionally substituted by hydroxy or C.sub.1-4 alkoxy, and the other represents the group R.sub.4 R.sub.5 NAlk-- in which Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms;R.sub.3, which may be in either the 2 or 3-position, represents the ##STR2## where X represents --CH.sub.2 --, --O-- or --S--; n represents zero, 1 or 2;m represents 2, 3 or 4; andR.sub.7 represents hydrogen, alkyl, alkenyl, aralkyl, or C.sub.2-6 alkyl substituted by hydroxy or alkoxy; andR.sub.8 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl, acyloxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkyloxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxy or alkoxy, or the group NR.sub.10 R.sub.11 ; with the provisos thatwhere R.sub.2 represents the group R.sub.4 R.sub.
    Type: Grant
    Filed: October 21, 1985
    Date of Patent: October 11, 1988
    Assignee: Glaxo Group Limited
    Inventors: John Bradshaw, Duncan B. Judd, Barry J. Price, John W. Clitherow, John W. M. Mackinnon, Linda Carey, Roger Hayes
  • Patent number: 4764612
    Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the variables are as defined in the specification.The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.Also disclosed are intermediates in the preparation of the compounds of the formula (I).
    Type: Grant
    Filed: February 6, 1986
    Date of Patent: August 16, 1988
    Assignee: Glaxo Group Limited
    Inventors: John W. Clitherow, John Bradshaw, John W. M. Mackinnon, Barry J. Price, Michael Martin-Smith, Duncan B. Judd
  • Patent number: 4670448
    Abstract: The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the substituents are defined in the detailed description.The compounds show pharmaceutical activity as selective histamine H.sub.2 -antagonists.
    Type: Grant
    Filed: February 10, 1983
    Date of Patent: June 2, 1987
    Assignee: Glaxo Group Limited
    Inventors: John W. Clitherow, John Bradshaw, John W. M. Mackinnon, Duncan B. Judd, David E. Bays, Roger Hayes, Andrew Pearce
  • Patent number: 4571394
    Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichQ represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4- positions:Z represents one of the groups ##STR2## where X represents NCN, NSO.sub.2 Methyl, NSO.sub.2 Phenyl or CHNO.sub.2. The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.
    Type: Grant
    Filed: July 23, 1982
    Date of Patent: February 18, 1986
    Assignee: Glaxo Group Limited
    Inventors: Roger Hayes, David E. Bays, John W. M. MacKinnon
  • Patent number: 4536508
    Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, which show pharmacological activity as selective histamine H.sub.2 -antagonists.
    Type: Grant
    Filed: February 18, 1983
    Date of Patent: August 20, 1985
    Assignee: Glaxo Group Limited
    Inventors: John W. Clitherow, Barry J. Price, John Bradshaw, Michael Martin-Smith, John W. M. Mackinnon, Duncan B. Judd, Roger Hayes
  • Patent number: 4518598
    Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, and hydrates thereof. The substituents are defined in the specification.The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.
    Type: Grant
    Filed: January 9, 1984
    Date of Patent: May 21, 1985
    Assignee: Glaxo Group Limited
    Inventors: Roger Hayes, David E. Bays, John W. M. Mackinnon, Linda Carey, Philip Blatcher
  • Patent number: 4507296
    Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts or hydrates thereof, in which the substituents are defined later in the specification.The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.
    Type: Grant
    Filed: January 9, 1984
    Date of Patent: March 26, 1985
    Assignee: Glaxo Group Limited
    Inventors: Roger Hayes, David E. Bays, John W. M. Mackinnon, Linda Carey
  • Patent number: 4442110
    Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichR.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen, C.sub.1-10 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl or alkyl substituted by hydroxy, alkoxy, amino, alkylamino, dialkylamino or cycloalkyl, or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered alicyclic heterocyclic ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom;Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms;Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, the furan ring optionally bearing a further substituent R.sub.
    Type: Grant
    Filed: November 24, 1981
    Date of Patent: April 10, 1984
    Assignee: Glaxo Group Limited
    Inventors: John W. Clitherow, John Bradshaw, John W. M. Mackinnon, Barry J. Price, Michael Martin-Smith, Duncan B. Judd
  • Patent number: 4410523
    Abstract: The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichR.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen, C.sub.1-10 alkyl, cycloalkyl, alkenyl, aralkyl, trifluoroalkyl, heteroaralkyl, or alkyl substituted by hydroxy, alkoxy, amino, alkylamino, dialkyamino or cycloalkyl, or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups, or a hydroxy group and/or may contain another heteroatom selected from oxygen and sulphur;Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms and is attached to the cyclohexadiene ring at either the 4- or 5- position;X represents --CH.sub.2 or --O--;m represents 2, 3, 4 or 5 and when X is --O-- the chain (CH.sub.2).sub.
    Type: Grant
    Filed: October 22, 1980
    Date of Patent: October 18, 1983
    Assignee: Glaxo Group Limited
    Inventors: William D. Ollis, Barry J. Price, Linda Carey, Roger Hayes, John W. Clitherow, John Bradshaw, John W. M. Mackinnon
  • Patent number: 4323566
    Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichR.sub.1 and R.sub.2, which may be the same of different, each represent hydrogen, C.sub.1 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl, or alkyl substituted by hydroxy, alkoxy, amino alkylamino dialkylamino or cycloalkyl or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom which is oxygen or sulphur;Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms,Q represents a furan or thiophene ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5- positions, the furan ring optionally bearing a further substituent R.sub.
    Type: Grant
    Filed: February 29, 1980
    Date of Patent: April 6, 1982
    Assignee: Glaxo Group Limited
    Inventors: John W. Clitherow, Barry J. Price, John Bradshaw, Michael Martin-Smith, John W. M. MacKinnon, Duncan B. Judd, Linda Carey
  • Patent number: 4318913
    Abstract: The invention relates to compounds of the formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichR.sub.1 and R.sub.2 represent hydrogen, an aliphatic or cycloaliphatic group, or R.sub.1 and R.sub.2 together with the nitrogen atom form a 5 to 10 membered heterocyclic ring:Alk represents a straight or branched alkylene chain;Q represents furan, thiophen or benzene ring which is incorporated into the rest of the molecule;X represents --CH.sub.2 --, ##STR2## --O-- or --S-- whereR.sub.6 represents hydrogen or methyl;n represents zero, 1 or 2;m represents 2, 3 or 4;R.sub.3 represents hydrogen, a substituted or unsubstituted aliphatic or aryl group and;R.sub.4 and R.sub.5, which may be the same or different, each represent hydrogen, a substituted or unsubstituted aliphatic, aryl, or together with the nitrogen atom form a heterocyclic group.
    Type: Grant
    Filed: April 26, 1979
    Date of Patent: March 9, 1982
    Assignee: Glaxo Group Limited
    Inventors: John W. Clitherow, John Bradshaw, John W. M. Mackinnon, Barry J. Price, Michael Martin-Smith, Duncan B. Judd